Jill M. Broadfoot Net Worth

The estimated Net Worth of Jill Marie Broadfoot is at least $569 ezer dollars as of 31 May 2024. Ms Broadfoot owns over 5,000 units of Atyr Pharma Inc stock worth over $53,124 and over the last 20 years she sold LIFE stock worth over $0. In addition, she makes $516,109 as Chief Financial Officer at Atyr Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Broadfoot LIFE stock SEC Form 4 insiders trading

Ms has made over 17 trades of the Atyr Pharma Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently she bought 5,000 units of LIFE stock worth $8,950 on 31 May 2024.

The largest trade she's ever made was buying 60,000 units of Atyr Pharma Inc stock on 7 January 2011 worth over $600. On average, Ms trades about 6,545 units every 184 days since 2004. As of 31 May 2024 she still owns at least 27,960 units of Atyr Pharma Inc stock.

You can see the complete history of Ms Broadfoot stock trades at the bottom of the page.

Ms. Jill M. Broadfoot biography

Jill M. Broadfoot is the Chief Financial Officer at Atyr Pharma Inc.

What is the salary of Ms Broadfoot?

As the Chief Financial Officer of Atyr Pharma Inc, the total compensation of Ms Broadfoot at Atyr Pharma Inc is $516,109. There are 2 executives at Atyr Pharma Inc getting paid more, with Dr. Sanjay S. Shukla having the highest compensation of $702,046.

How old is Ms Broadfoot?

Ms Broadfoot is 59, she's been the Chief Financial Officer of Atyr Pharma Inc since . There are 6 older and 6 younger executives at Atyr Pharma Inc. The oldest executive at Atyr Pharma Inc is Paul Schimmel, 79, who is the Independent Director.

What's Ms Broadfoot's mailing address?

Jill's mailing address filed with the SEC is 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121.

Insiders trading at Atyr Pharma Inc

Over the last 16 years, insiders at Atyr Pharma Inc have traded over $27,288,922 worth of Atyr Pharma Inc stock and bought 966,653 units worth $5,761,237 . The most active insiders traders include James C Blair, Gregory T Lucier és Craig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of $34,257. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth $8,950.

What does Atyr Pharma Inc do?

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation

Complete history of Ms Broadfoot stock trades at Acelrx Pharmaceuticals Inc, Atyr Pharma Inc és Otonomy Inc

Atyr Pharma Inc executives and stock owners

Atyr Pharma Inc executives and other stock owners filed with the SEC include:

• Dr. Sanjay S. Shukla,
  Pres, CEO & Director
• Sanjay Shukla,
  President, Chief Executive Officer, Director
• Jill M. Broadfoot,
  Chief Financial Officer
• Nancy E. Denyes Krueger,
  Gen. Counsel & Corp. Sec.
• Jill Broadfoot,
  Chief Financial Officer
• Nancy Denyes,
  General Counsel and Corporate Secretary
• Paul Schimmel,
  Independent Director
• John Clarke,
  Independent Chairman of the Board
• Svetlana Lucas,
  Independent Director
• Jeffrey Hatfield,
  Independent Director
• Jane Gross,
  Independent Director
• Timothy Coughlin,
  Independent Director
• Dr. David J. King,
  Scientific Consultant
• Dr. Melissa A. Ashlock,
  Sr. Advisor
• Dr. Ying J. Buechler,
  Exec. Director of Biologics Devel. & Manufacturing
• Peter Villiger,
  VP of Corp. Devel.
• Ashlee Dunston,
  Director of Investor Relations & Corp. Communications
• Xiang-Lei Yang Ph.D.,
  Founder
• Donald W Grimm,
  Director
• Arnold J Levine,
  Director
• Ronald Asbury Andrews,
  President, Medical Sciences
• George F Jr Adam,
  Director
• David C Uprichard,
  Director
• Gregory T Lucier,
  CEO
• Kelli Richard,
  Chief Accounting Officer
• Bradley G Lorimier,
  Director
• Peter Michael Leddy,
  SVP, Human Resources
• Balakrishnan S Iyer,
  Director
• Raymond V Dittamore,
  Director
• Per A Peterson,
  Director
• Craig J Mundie,
  Director
• Mark P Stevenson,
  President & COO
• Ora H. Pescovitz,
  Director
• Ronald A Matricaria,
  Director
• John A Cottingham,
  Chief Legal Officer
• David F Hoffmeister,
  Chief Financial Officer
• Claude Benchimol,
  SVP, Advanced Genomic Systems
• William H Longfield,
  Director
• Nicolas Barthelemy,
  President, Cell Systems
• John L Miller,
  President - Genetic Systems
• Mark Sean O'donnell,
  SVP, Global Operations & Serv.
• Peter Dansky,
  Pres, Molecular Biology Sys
• Bernd Brust,
  Pres, Commercial Operations
• Paul David Grossman,
  SVP, Corporate Strategy & Dev.
• W Ann Reynolds,
  Director
• Joseph C Beery,
  SVP, Chief Information Officer
• William S Shanahan,
  Director
• James C Blair,
  Director
• John Mendlein,
  Director
• Sara Zaknoen,